"Promising Results from Tongxinluo Trial Raise Questions about Active Ingredients"
A clinical trial conducted in China has shown that the traditional Chinese medicine compound Tongxinluo reduced major adverse cardiac and cerebrovascular events and cardiac deaths in patients with acute myocardial infarction. However, the active ingredients of Tongxinluo remain unclear, as the study did not provide a breakdown of the specific plants and insects used or their quantities. The trial also had limitations, including a missing mechanism of action, suboptimal adherence to guideline-directed therapy, and a low-risk patient cohort, which may limit the generalizability of the findings. Further research is needed to confirm and expand upon these results.
